1. Home
  2. CDXS vs SCD Comparison

CDXS vs SCD Comparison

Compare CDXS & SCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDXS
  • SCD
  • Stock Information
  • Founded
  • CDXS 2002
  • SCD 2003
  • Country
  • CDXS United States
  • SCD United States
  • Employees
  • CDXS N/A
  • SCD N/A
  • Industry
  • CDXS Major Chemicals
  • SCD Trusts Except Educational Religious and Charitable
  • Sector
  • CDXS Industrials
  • SCD Finance
  • Exchange
  • CDXS Nasdaq
  • SCD Nasdaq
  • Market Cap
  • CDXS 254.3M
  • SCD 264.7M
  • IPO Year
  • CDXS 2010
  • SCD N/A
  • Fundamental
  • Price
  • CDXS $2.44
  • SCD $15.74
  • Analyst Decision
  • CDXS Buy
  • SCD
  • Analyst Count
  • CDXS 2
  • SCD 0
  • Target Price
  • CDXS $11.00
  • SCD N/A
  • AVG Volume (30 Days)
  • CDXS 1.1M
  • SCD 62.6K
  • Earning Date
  • CDXS 10-30-2025
  • SCD 01-01-0001
  • Dividend Yield
  • CDXS N/A
  • SCD 9.63%
  • EPS Growth
  • CDXS N/A
  • SCD N/A
  • EPS
  • CDXS N/A
  • SCD N/A
  • Revenue
  • CDXS $57,164,000.00
  • SCD N/A
  • Revenue This Year
  • CDXS $12.88
  • SCD N/A
  • Revenue Next Year
  • CDXS $21.64
  • SCD N/A
  • P/E Ratio
  • CDXS N/A
  • SCD N/A
  • Revenue Growth
  • CDXS N/A
  • SCD N/A
  • 52 Week Low
  • CDXS $1.90
  • SCD $11.33
  • 52 Week High
  • CDXS $6.08
  • SCD $15.87
  • Technical
  • Relative Strength Index (RSI)
  • CDXS 37.30
  • SCD 69.49
  • Support Level
  • CDXS $2.37
  • SCD $15.36
  • Resistance Level
  • CDXS $2.54
  • SCD $15.59
  • Average True Range (ATR)
  • CDXS 0.12
  • SCD 0.11
  • MACD
  • CDXS -0.01
  • SCD 0.03
  • Stochastic Oscillator
  • CDXS 30.00
  • SCD 87.76

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About SCD LMP Capital and Income Fund Inc.

Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.

Share on Social Networks: